Anti-human DDR1 Antibody AB2041

Catalog Number Product Size Price
A1016-100 Anti-human DDR1 Antibody AB2041 100µg $185 Order
A1016-200 Anti-human DDR1 Antibody AB2041 200µg $325 Order
A1016-500 Anti-human DDR1 Antibody AB2041 500µg $545 Order

Product Specifications

Catalog Number A1016
Product Name Anti-human DDR1 antibody AB2041
Source Recombinant anti-human DDR1 mAb produced from HEK293 cells
Clone AB2041 (VH and VL sequences are derived from PCT publication, WO2014047624A1)
Species Reactivity Human
Isotype Mouse IgG2a
Purity >95%
Formulation 1x PBS, pH6.8; Sterile
Stability & Storage 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw
Protein Aggregation Not obvious on SDS-PAGE
Application Flow cytometry, ELISA, cell-based assay
Product Datasheet: Download PDF

Representative Data

A. Flow cytometry

Detection of human DDR1 on Human DDR1-CHO-K1 cells (Cat. #C3030) by flow cytometry. Anti-human DDR1 antibody AB2041 was incubated with human DDR1-CHO-K1 cells (Cat. #C3030), followed by staining with PE-anti-mouse IgG.

B. SDS-PAGE analysis of anti-human DDR1 AB2041 (Cat. # A1016)


DDR1 (discoidin domain receptor tyrosine kinase 1), also known as CD167, CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, EDDR1, MCK10, NTRK4, and PTK3A, is a receptor tyrosine kinase (RTK) and belongs to a subfamily of tyrosine kinase receptors with a homology region to the Dictyosteliumdiscoideum protein discoidin I in its extracellular domain. DDR1 consists of three regions (an extracellular ligand binding domain, a transmembrane domain, and an intracellular region containing a kinase domain), with its kinase activity induced by receptor-specific ligand binding. Collagen binding to DDR1 stimulates its autophosphorylation, activating kinase activity and signaling to downstream signaling pathways. DDR1 expression is restricted to epithelial cells, particularly in the kidney, lung, gastrointestinal tract, and brain and is significantly over-expressed in several human tumors from breast, ovarian, esophageal, and brain. DDR1 plays a key role in the development and progression of breast and ovarian cancer and is a promising therapeutic target.


Johnson, J. D., Edman, J. C., Rutter, W. J., Proc. Nat. Acad. Sci. 90: 5677-5681, 1993.
Chen, L., et al, Frontiers in Cell and Dev. Bio. 9: 747314, 2021.
Letinger, B.,Int Rev Cell Mol Biol., 310: 39-87, 2014.
Vogel, W., et al., Mol. Cell, 1: 13–23, 1997.